NASDAQ: NDRAEndra Life Sciences Inc Stock
$0.24-0.02 (-7.69%)
Updated Apr 25, 2024
NDRA Price
$0.24
Fair Value Price
$0.38
Market Cap
$2.67M
52 Week Low
$0.22
52 Week High
$2.79
P/E
-0.15x
P/B
0.47x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.06M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.19
Operating Cash Flow
-$10M
Beta
0.92
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NDRA Overview
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NDRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NDRA ($0.24) is undervalued by 36.87% relative to our estimate of its Fair Value price of $0.38 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NDRA ($0.24) is significantly undervalued by 36.87% relative to our estimate of its Fair Value price of $0.38 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NDRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NDRA due diligence checks available for Premium users.
Be the first to know about important NDRA news, forecast changes, insider trades & much more!
NDRA News
Valuation
NDRA fair value
Fair Value of NDRA stock based on Discounted Cash Flow (DCF)
Price
$0.24
Fair Value
$0.38
Undervalued by
37.39%
NDRA ($0.24) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NDRA ($0.24) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NDRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NDRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.15x
Industry
38.32x
Market
40.97x
NDRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.47x
Industry
4.15x
NDRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NDRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.5M
Profit Margin
0%
NDRA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.8M
Liabilities
$1.1M
Debt to equity
0.19
NDRA's short-term assets ($3.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NDRA's short-term assets ($3.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NDRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NDRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.2M
Investing
$2.3k
Financing
$1.7M
NDRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NDRA vs Diagnostic & Research Stocks
Endra Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.